Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My point exactly. Would be a waste of that audience's time and an opportunity lost to be discussing old data. Not how I've seen other companies handle their KOL events. Anyway, if they in fact do it without the new data, I will have a low opinion of the management's competence.
My guess is we could get hip data tomorrow premarket to draw the audience for Monday (based on my experience with another KOL I've been through for another company). I'll probably be proven wrong haha.
LGND to Acquire Crystal Bioscience, the Leader in Chicken-derived Fully-human Antibody Generation, for $25 Million in Cash plus Additional Potential Payments
http://www.businesswire.com/news/home/20171004006266/en/Ligand-Acquire-Crystal-Bioscience-Leader-Chicken-derived-Fully-human/
- Gains complementary antibody technology and discovery lab, new revenue streams and four fully-funded partnerships with potential for milestones and royalties
- Transaction expected to be accretive to revenue and earnings beginning in 2018
- Ligand’s portfolio now has more than 160 fully-funded Shots on Goal
Excellent work ash111! Congrats but IMO this is just warming up. With positive ppd data this is going double digits IMO. Even SAGE reporting positive p3 ppd data could lift this up before they report their own data in December.
Today's headline was a stretch indeed for a mouse study. I'm looking forward to their p2 hip fracture recovery data though. It is expected this month.
VKTX - Anyone have any thoughts on upcoming VK5211 hip fracture recovery phase 2 data?
KOL event on Monday.
http://ir.vikingtherapeutics.com/2017-09-25-Viking-Therapeutics-to-Host-Key-Opinion-Leader-Event-to-Discuss-Musculoskeletal-Therapeutics-in-Hip-Fracture-and-Other-Settings
No other competitor in the space in a $1B+ market. SARMs already used off label by pro athletes and bodybuilders for muscle recovery with good results.
Penny stock but I see decent potential upside. Company owned 40% by LGND.
TIA.
Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)
Treatment with VK0214 led to Significant Reductions in Plasma and Tissue Levels of Very Long Chain Fatty Acids (VLCFAs)
Tissue Effects Suggest Promising CNS Activity Following 25 Weeks of Exposure
http://www.prnewswire.com/news-releases/viking-therapeutics-announces-top-line-results-from-proof-of-concept-study-of-vk0214-in-in-vivo-model-of-x-linked-adrenoleukodystrophy-x-ald-300530670.html
I think we will see a similar move if we get positive interim data from the registration trial mid next year and if MRK follows up with an offer. Risky binary but the opportunity is there, IMO.
Just amazing. This is WITHOUT data. Can't wait for ppd readout in December. If SAGE reports positive p3 PPD earlier, then this will get a nice lift too, IMO.
Yes! This seems to be an afternoon runner.
Exactly. Ligand stands to gain a lot of Viking succeeds. 40% ownership is no joke. Having said that, I do wish they had gone with someone other than Lincoln Park. These guys don't have a good reputation.
It is indeed. I'm not sure if it is going to be a rehash of data already presented or something materially new. Conferences usually require that presenters share new data. Not sure what the policy is with this conference. Anyway I think this conference will just be a bonus for October. Hip data at the KOL (most likely) will be the key value driver.
That's what I thought as well. By the way, I'm curious if we will get any new info at AASLD on Oct 20-24.
Besides musculoskeletal data, do we anticipate any other readouts in Q4? I suppose NASH update won't be coming until H1'18.
DVAX - Dynavax explores options for Hepatitis B drug - sources | Reuters
https://in.reuters.com/article/us-dynavax-vaccines-exclusive/exclusive-immunotherapy-developer-dynavax-explores-options-for-hepatitis-b-drug-sources-idINKCN1C4353
$2 and close to 10k volume after hours. Next week should be fun and hopefully data on the 9th.
Have a great weekend all!
ACER +32% - Not sure why (eom)
MRNS - Bain Capital Life Science discloses 15.9% stake from last offering at $3.75
http://ih.advfn.com/p.php?pid=nmona&article=75750071&adw=1126416
What a day! Will be fun going into data next month. And of course, the right results could make it even better. GL to you and all on board!
ZYNE +64% on Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome
https://globenewswire.com/news-release/2017/09/28/1134232/0/en/Zynerba-Pharmaceuticals-Announces-Positive-Top-Line-Results-in-ZYN002-Open-Label-Phase-2-FAB-C-Study-in-Children-with-Fragile-X-Syndrome.html
I agree. Another bio I follow had discussed their new data at their KOL event with analysts and bankers. Would make no sense to have a KOL event without a strong agenda.
I also really like the fact that they are spun off from, and still owned in majority by Ligand. Ligand is a successful company with commercial products and even VK5211 was developed by Ligand. I feel very good about the upcoming phase 2 readout.
Thanks BrazenBull! Glad to be here. I think I found this company at the right time as we are getting close to new data. GL to us all!
I think they won't ahab. Their goal IMO is to meet endpoints for PISCES, get AA, and sell the company to MRK for about $1B (using T-VEC as a benchmark). I don't believe their goal was ever to become a big pharma. PD has always mentioned in presentations that their goal is to have a big pharma take the treatment to market. I'd be content with a BO at ~$30 a share. While it's a super binary bet, based on the data they have collected so far and the biomarkers they have at their disposal to pick the right patients, I think they will meet their 30% ORR goal. I am a bit concerned about why the trial hasn't started yet though. Anyway I'm giving them the benefit of the doubt as this trial will have multiple locations in the US and Australia which might be the reason for the delay.
I agree. They have full control over when they can schedule a KOL event and it wouldn't make sense to have it a week or two before data. I think we will have data on or before October 9th.
Last minute presentation at Cantor Fitzgerald?
http://www.prnewswire.com/news-releases/oncosec-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-300526031.html
Thanks Lynx7! Looking forward to learning from and contributing to the board.
Thanks greens12. I agree on the confidence and timing as well. Will do indeed!
Hello all! New here. Started position today. Looking forward to October 9th KOL event. Isn't it likely that they will release the p2 VK5211 data the same day to make the most out of this KOL event?
GNCA -55% /PM (eom)
Now that it's over $5, mutual funds can buy MRNS again. I think we will see continued institutional buying in the coming days. I wouldn't be surprised if this trades at $7-8 before PPD data.
It was nice to see Bain Capital as lead investor in the recent raise at $3.75. Given where and how it's trading, the demand for shares seems clearly high. A positive p2 PPD readout could send this back to double digits IMO. SAGE's current valuation is now supported just by its p2 PPD data from last year. There is not a good basis for the valuation gap between the two companies IMO. With identical drugs and MoA, MRNS data next quarter should be positive as well and MRNS share price should go higher.
Getting Ready for Gilead’s CAR-T
http://www.barrons.com/articles/getting-ready-for-gileads-car-t-1506367009
In A First, Pfizer Spins Out Biotech Firm With $103 Million In Funding
https://www.forbes.com/sites/elliekincaid/2017/09/25/in-a-first-pfizer-spins-out-biotech-firm-with-103-million-in-funding/#4bb4cb07630f
Michelin wants to reinvent the wheel for the driverless age
- Airless, indestructible, and 3D-printed from orange zest (among other biomaterials)
https://www.theverge.com/2017/9/24/16126356/michelin-3d-printing-reinvent-the-wheel-driverless-age
Scientists create world’s first ‘molecular robot’ capable of building molecules
https://scienmag.com/scientists-create-worlds-first-molecular-robot-capable-of-building-molecules/
AKTX +76% on FDA meeting update
http://www.nasdaq.com/press-release/akari-therapeutics-announces-regulatory-progress-following-fda-meeting-20170921-00293
ESMO 2017 Congress Highlights
http://www.sitcancer.org/aboutsitc/media-room/meeting-highlights/2017/esmo
Don't mean to take anything away from EP IL-12 btw. If successful in melanoma anti PD-1 nonresponders, this will be big by itself as that market is $500M. But having the multigene candidate show even very early results would sweeten up the premium IMO.
A theory that I just thought of just for fun. It is highly unlikely to be true but let me share it anyway just for fun's sake since we have nothing much going on...
Could it be that they are intentionally delaying the registration trial to give this multigene pipeline some time to gain traction before MRK gets the chance to decide on the company on data from the reg trial? I personally think they are better off going to the table with MRK with more than just EP IL-12 to offer.
Again, speculative to the max and just for fun.